Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Palatin Technologies Announces Extension of Research Collaboration and License Agreement with AstraZeneca

Published: Wednesday, December 10, 2008
Last Updated: Wednesday, December 10, 2008
Bookmark and Share
Both companies enter into clinical trial sponsored research agreement to conduct a study of the effects of melanocortin receptor specific compounds.

Palatin Technologies, Inc. has announced an extension of its exclusive research collaboration and license agreement with AstraZeneca to discover, develop and commercialize compounds that target melanocortin receptors and the signing of a clinical trial sponsored research agreement.

Under the extension to the license agreement, Palatin will receive an upfront payment of $1.6 million and AstraZeneca has been granted licenses to additional compounds and patents.

Additionally, the research collaboration term has been extended, with Palatin contributing scientific expertise and AstraZeneca supporting Palatin's internal activities at an agreed full-time equivalent rate.

Under the clinical trial sponsored research agreement, Palatin will be responsible for conducting a study of the effects of melanocortin receptor specific compounds on food intake, obesity and other metabolic parameters.

Palatin will be eligible, in the near future, for milestone payments totaling $5 million in connection with the collaboration and license agreement.

Under terms of the original collaboration and license agreement signed in January 2007, Palatin received an upfront payment of $10 million from AstraZeneca and is eligible for milestone payments totalling $300 million, with up to $180 million contingent upon development and regulatory milestones and the balance on achievement of sales targets, together with the payment of stepped royalties on product sales to double digit rates, dependent on sales achieved. AstraZeneca is responsible for product commercialization, product discovery and development costs.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Monday, April 25, 2016
Astrazeneca Supports Crowd Sourcing Challenge to Find Cancer Therapies
AstraZeneca is making available preclinical data from over 50 of its medicines as part of the DREAM Challenge, an open innovation competition, to find the most synergistic drug combinations with the potential to treat cancer.
Wednesday, September 23, 2015
Astrazeneca Purchases Us Biologics Manufacturing Facility
AstraZeneca has added to its biologics manufacturing capability in the US with the purchase of a high-tech biologics bulk manufacturing facility from Amgen Inc.
Monday, September 14, 2015
AstraZeneca, Univ. of Manchester Partner
AstraZeneca and The University of Manchester have announced a collaboration harnessing clinical bioinformatics to deliver personalised healthcare for cancer patients.
Wednesday, September 09, 2015
AstraZeneca and Peregrine Pharmaceuticals to Collaborate
Collaboration on immuno-oncology combination clinical trial.
Friday, August 28, 2015
Medimmune Enters into Collaboration and License Agreement with Inovio
Agreement includes clinical-stage INO-3112 HPV cancer vaccine and preclinical collaboration to develop additional cancer vaccine candidates.
Thursday, August 20, 2015
Heptares, AstraZeneca Collaborate
The companies are set to enter into an agreement to develop novel immuno-oncology treatments for a range of cancers.
Monday, August 10, 2015
AstraZeneca, Isis Pharmaceuticals Collaborate
AstraZeneca and Isis Pharmaceuticals, Inc. have announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases.
Tuesday, August 04, 2015
AstraZeneca, Lilly to Study Immuno-Oncology Combination
This collaboration sets out to assess the efficacy of a combinatorial treatment in patients with advanced solid state tumors.
Monday, June 01, 2015
AstraZeneca to Invest in New Biologics Manufacturing Facility
New facility in Södertälje, Sweden, to support accelerating biologics portfolio.
Thursday, May 21, 2015
AstraZeneca and Montreal Heart Institute Partner
AstraZeneca and Montreal Heart Institute to screen 80,000 samples for cardiovascular and diabetes genetic traits.
Thursday, May 14, 2015
AstraZeneca and Abbott Partner
AstraZeneca and Abbott to develop companion diagnostic tests for tralokinumab in severe asthma.
Thursday, May 14, 2015
AstraZeneca and Harvard Stem Cell Institute Collaborate
Collaboration will develop the use of stem cells for diabetes research.
Wednesday, March 25, 2015
AstraZeneca Forms CRISPR Collaborations
AstraZeneca announces collaborations to use CRISPR technology for genome editing across its drug discovery platform.
Thursday, January 29, 2015
AstraZeneca To Expand Its Frederick Biologics Manufacturing Center
$200+ million investment to support company’s maturing biologics pipeline.
Tuesday, November 25, 2014
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!